Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on December 2, 2025. The filing addresses corporate governance matters specifically related to the amendment of executive employment agreements to correct clerical errors in documents originally dated November 26, 2025.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to the disclosure of executive compensation adjustments.
Material Changes
The primary material change disclosed is the correction of employment terms for two senior executives:
- David J. Moss (President and CEO): Base salary restated to $454,000 per annum. Stock option grant restated to 750,000 shares under the 2021 Stock Incentive Plan.
- Cory Ellspermann (CFO): Base salary restated to $240,000 per annum.
These amendments were executed to correct mistakes in the original agreements signed on November 26, 2025.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The document strictly reports the administrative correction of executive compensation terms.
Investor Verification Checklist
- Verify the full text of the employment agreement amendments filed as Exhibit 10.1 (David Moss) and Exhibit 10.2 (Cory Ellspermann).
- Confirm the impact of the 750,000 share option grant on the company's total outstanding share count and potential dilution.
- Review the original November 26, 2025 agreements to understand the nature of the "mistake" that necessitated these amendments.